| Patient number | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
Sex (M/F) | F | F | F | M | M | M | F | M | M | M | |
Age (years) | 37 | 42 | 49 | 42 | 44 | 41 | 30 | 32 | 64 | 54 | |
BMI (kg/m2) | 27.9 | 22.6 | 26.5 | 22.2 | 20.3 | 38 | 20.2 | 26.7 | 23.1 | 23.5 | |
Hypertension (yes/no) | N | N | Y | N | N | Y | N | N | N | N | |
Diabetes mellitus (yes/no) | N | N | N | N | N | N | N | N | N | N | |
Smoking history (yes/no) | N | N | N | N | N | Y | N | N | Y | N | |
Duration of LBP (months) | 96 | 12 | 14 | 29 | 7 | 37 | 96 | 72 | 36 | 84 | |
Implanted disc level | L4/5 | L4/5 | L4/5 | L4/5 | L4/5 | L4/5, L5/S1 | L4/5 | L4/5 | L4/5 | L4/5 | |
Preoperative VAS | 8 | 7 | 6 | 7 | 4 | 7 | 6 | 6 | 6 | 7 | |
Preoperative ODI | 40 | 34 | 30 | 50 | 32 | 72 | 54 | 32 | 32 | 60 | |
Preoperative Pfirrmann’s grade | IV | IV | IV | IV | IV | IV | IV | IV | IV | IV | |
Cell number (× 107/vial) | 4.7 | 5.3 | 5.4 | 5.3 | 5.4 | 5.0 | 5.3 | 5.0 | 5.2 | 4.7 | |
Cell viability (%) | 93.62 | 91.55 | 97.57 | 88.30 | 97.09 | 89.44 | 87.13 | 94.38 | 94.55 | 89.93 | |
Cell surface marker | CD44 (%) | 94.50 | 84.80 | 98.00 | 99.90 | 99.90 | 100 | 99.8 | 99.9 | 98.3 | 99.2 |
CD73 (%) | 98.40 | 98.60 | 99.90 | 100.00 | 99.60 | 100 | 100 | 100 | 99.9 | 99.9 | |
CD45 (%) | 1.00 | 0.81 | 0.20 | 0.48 | 0.51 | 0.75 | 0.19 | 0.49 | 0.7 | 0.67 | |
CD29 (%) | 90.80 | 97.50 | 99.80 | 99.90 | 99.90 | 100.00 | 100.00 | 100.00 | 100.00 | 99.90 | |
TGF-β receptor III | 98.20 | 99.10 | 99.60 | 100.00 | 99.70 | 99.10 | 99.90 | 100.00 | 99.40 | 99.80 |